Covid19-Sources

Original Article from The New England Journal of Medicine — Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titers that were 5.0- and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 following vaccination. Median binding antibody titers were 2.9- and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition, and NK cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1, and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.

Trivia Liste von mancherlei Querdenker-Ankündigungen.

The health effects of coronavirus disease 2019 (COVID-19) caused by the infection of SARS-CoV‑2 (severe acute respiratory syndrome coronavirus 2) are becoming increasingly clear as the pandemic spreads. In addition to the lungs, other organs are also affected, which can significantly influence morbidity and mortality. In particular, neurological symptoms involving the central nervous system can lead to acute or long-term consequences. The mechanisms of this neuropathogenesis of SARS-CoV‑2 infection and its relation to acute and chronic neurological symptoms are the subject of current studies investigating a potential direct and indirect viral infection of the nervous system. The following review summarizes the current status of neuropathological manifestations, molecular pathogenesis, possible infection pathways in the nervous system, and systemic effects. In addition, an overview of the Germany-wide CNS-COVID19 registry and collaborations is presented, which should contribute to a better understanding of the neurological symptoms of COVID-19.

Mit neuen Studien will das Unternehmen der Pandemie "einen Schritt voraus" sein. Luxemburgs Premierminister nach EU-Gipfel positiv getestet. Corona-News aus aller Welt

Researchers say new coronavirus started circulating before it surfaced in Wuhan

Explore a collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.

Review clinical data on the use of ivermectin for the treatment of COVID-19.

Dr. Sucharit Bhakdi und seine Frau Dr. Karina Reiss haben wunderbare Neuigkeiten. Sie berichten begeistert von jüngst veröffentlichten Studienergebnissen, die, wie sie sagen, die entscheidende Nachricht des Jahres beinhalten: "Alle Menschen haben bereits die so gewünschte Herdenimmunität. Nicht 75% der Personen, sondern über 90% – ohne, dass man impfen muss." "Also das, was die Impfung eigentlich bewerkstelligen sollte, hat der menschliche Körper schon gebildet?", frage ich nach. – "Das haben diese Studien gezeigt!" An diesem Tag der Freude, wie der Immunologe ihn nennt, sprechen die beiden Wissenschaftler mit mir über das Prinzip der erworbenen Immunität, Antikörper, über schützende Lymphozyten, und das vortrainierte Immunsystem. Gegen den Irrweg der Impfkampagne erheben Bhakdi und Reiss schwere Vorwürfe, ebenso wie gegen die verkommenen Institutionen dieses Landes. Ein Land, in dem man zwar seine Meinung äußern kann, dann jedoch mit entsprechenden Strafmaßnahmen zu rechnen hat. Ein Land, welches sie verlassen werden, falls ihr letzter Ausweg scheitert: die politische Initiative. Prof. Dr. Sucharit Bhakdi ist deutscher Facharzt für Infektionsepidemiologie und Mikrobiologie. Er studierte Humanmedizin an der Universität Bonn, war bis zu seinem Ruhestand Professor an der Universität Mainz und leitete bis dahin das Institut für medizinische Mikrobiologie und Hygiene. Seine wissenschaftlichen Forschungen wurden mehrfach ausgezeichnet. Prof. Dr. Karina Reiss ist deutsche Biochemikerin und Hochschullehrerin. Sie promovierte und habilitierte an der Medizinischen Fakultät der Universität Kiel, im Fach Biochemie. Beide sind Eltern eines gemeinsamen Sohnes. Im Gespräch erwähnte Studien: Studie 1: Spikes were produced in and ejected from cells in contact with the bloodstream.(https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075) Studie 2: Circulating, specific SARS-CoV-2 IgG and IgA antibodies became detectable 1-2 weeks after application of mRNA vaccines. (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499, https://doi.org/10.1016/j.cell.2021.06.005) Studie 3: SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. (https://www.sciencedirect.com/science/article/pii/S2352396421002036) Studie 4: Spike-specific IgG and IgA levels rise further one day after second injection of mRNA (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499) Karina Reiss, Sucharit Bhakdi: Corona unmasked. Neue Daten, Zahlen, Hintergründe. https://bit.ly/35MeFai Reiss/Bhakdi: Corona Fehlalarm? Zahlen, Daten und Hintergründe. https://bit.ly/3d43sG7 Eine FILMPRODUKTION von Tobias Jansen und Lukas Karl Website http://jansen-film.de http://lukomotiv.de YouTube https://www.youtube.com/tobiasjansen https://youtube.com/LuKaPhotography Instagram https://instagram.com/tobsjans https://instagram.com/luko.motiv YOUTUBE Gunnar Kaiser: https://www.youtube.com/c/gunnarkaisertv YOUTUBE Gunnar Kaiser Unchained: https://www.youtube.com/user/philosophischleben VIMEO https://vimeo.com/gunnarkaiser LBRY https://lbry.tv/@kaisertv:a RUMBLE https://rumble.com/user/GunnarKaiser WEBSITE http://www.gunnarkaiser.de BLOG http://www.kaisertv.de TELEGRAM https://t.me/gunnarkaisertv TWITTER https://twitter.com/GunnarKaiser MERCHANDISING https://gunnarkaiser.com/ PODCAST iTunes https://goo.gl/dNuWVF Spotify https://goo.gl/qBVZvy Soundcloud https://goo.gl/rHhkg1 Mein Projekt REFUGIUM: https://youtu.be/LX0ZKtyrI4E Mein Roman "Unter der Haut": https://bit.ly/32NZnkt EXKLUSIV Über 100 exklusive Videos und Artikel sowie alle Informationen zu Vorträgen, Seminaren und Lesungen ab einem Euro im Monat: - KaiserTV-Kanalmitgliedschaft: https://bit.ly/35diV1x - Substack: https://gunnarkaiser.substack.com - Patreon: https://www.patreon.com/gunnarkaiser UNTERSTÜTZEN: KONTO: Gunnar Kaiser; IBAN DE38 3704 0044 0162 5706 00 PAYPAL: http://www.paypal.me/gunnarkaiser BITCOIN bc1qumd4n2wez42r8fp5qxqtf2u8edn2vwsz3nt4a8 1J8bPrXymYYcPN9Fkc6QFyxA4UfCJWh2rS BITCOIN CASH qpz6njg2h08vqwdqhw39vy3a5wxhwxykngs2hrzawm DASH XwPQi8PtevRgLzWsXhwtRcGe6unQFbQ7yS MONERO 44SP24XRF7b3sGNo3ejq93BL2SvniLWZ3QbFYH78VJiLDLayeaCX1AsakzK3piMh5B4skzhARzw1BQNe5EDJb7Bf59AL7eQ

Almost half of children who contract covid-19 may have lasting symptoms, which should factor into decisions on reopening schools, reports Helen Thomson

When will vaccines for children be available? ➡️ Pfizer anticipates having initial results of lower-dose Phase 2/3 trials in September for 5- to 11-year-old kids; results for kids 2-<5 shortly after; kids 6-<24 months old in October or November. #COVID19 https://t.co/F1dEYZNhZt

Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, despite being relatively young and having only mild to moderate acute COVID-19 symptoms.

Transparenz ist der Schlüssel für Vertrauen in Impfstoffe. Die in Deutschland gemeldeten Verdachtsfälle von Nebenwirkungen oder Impfkomplikationen im zeitlichen Zusammenhang mit der Impfung gegen COVID-19 erfasst und bewertet das Paul-Ehrlich-Institut kontinuierlich. Das Ergebnis finden Sie in unserem aktuellen Sicherheitsbericht für den Zeitraum vom 27.12.2020 bis 30.04.2021.

Key Points. The RBD of SARS-CoV-2 shares sequence similarity with an ancient lectin family known to bind blood group antigens.SARS-CoV-2 RBD binds the blood gro

Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, despite being relatively young and having only mild to moderate acute COVID-19 symptoms.

Objective To estimate changes in life expectancy in 2010-18 and during the covid-19 pandemic in 2020 across population groups in the United States and to compare outcomes with peer nations. Design Simulations of provisional mortality data. Setting US and 16 other high income countries in 2010-18 and 2020, by sex, including an analysis of US outcomes by race and ethnicity. Population Data for the US and for 16 other high income countries from the National Center for Health Statistics and the Human Mortality Database, respectively. Main outcome measures Life expectancy at birth, and at ages 25 and 65, by sex, and, in the US only, by race and ethnicity. Analysis excluded 2019 because life table data were not available for many peer countries. Life expectancy in 2020 was estimated by simulating life tables from estimated age specific mortality rates in 2020 and allowing for 10% random error. Estimates for 2020 are reported as medians with fifth and 95th centiles. Results Between 2010 and 2018, the gap in life expectancy between the US and the peer country average increased from 1.88 years (78.66 v 80.54 years, respectively) to 3.05 years (78.74 v 81.78 years). Between 2018 and 2020, life expectancy in the US decreased by 1.87 years (to 76.87 years), 8.5 times the average decrease in peer countries (0.22 years), widening the gap to 4.69 years. Life expectancy in the US decreased disproportionately among racial and ethnic minority groups between 2018 and 2020, declining by 3.88, 3.25, and 1.36 years in Hispanic, non-Hispanic Black, and non-Hispanic White populations, respectively. In Hispanic and non-Hispanic Black populations, reductions in life expectancy were 18 and 15 times the average in peer countries, respectively. Progress since 2010 in reducing the gap in life expectancy in the US between Black and White people was erased in 2018-20; life expectancy in Black men reached its lowest level since 1998 (67.73 years), and the longstanding Hispanic life expectancy advantage almost disappeared. Conclusions The US had a much larger decrease in life expectancy between 2018 and 2020 than other high income nations, with pronounced losses among the Hispanic and non-Hispanic Black populations. A longstanding and widening US health disadvantage, high death rates in 2020, and continued inequitable effects on racial and ethnic minority groups are likely the products of longstanding policy choices and systemic racism. Data sharing: Requests for additional data and analytic scripts used in this study should be emailed to RKM (Ryan.Masters@colorado.edu).

This cross-sectional study examines the association of the COVID-19 pandemic with estimated life expectancy by race/ethnicity in the US.

Despite poor protection after two shots, an extra dose helps some

Die Maskenpflicht anpassen ja, abschaffen keinesfalls, kommentiert Lars Fischer

Background An increasing number of reports have described the COVID-19 associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus stat...

"I feel guilty because I know I brought it home from work and at the time we were told it doesn’t affect children. To be ill for over a year when you’re only 10 - that’s a tenth of your life.”

This cross-sectional study uses administrative health care data on 2.9 million households from the first 45 weeks of 2020 to assess the association between social gatherings and SARS-CoV-2 transmission by studying whether COVID-19 rates increase after birthdays in a household.

Northern town of Binyamina-Giv'at Ada says contagion appeared to come from people who arrived from abroad; school won't open Sunday, the last day of classes before summer

The global race to develop a COVID-19 vaccine is on. Here are the different types of vaccines and how your body uses them to develop immunity.

The 1st direct antiviral drug intervention—monoclonal antibody cocktail—to improve covid survival Preprint of #RECOVERY https://t.co/21Kf4Gl2Mg Benefit in hospitalized patients who have not developed an antibody response; potential harm in those who had https://t.co/l2fXJtd3yJ https://t.co/EqrXqbl0Rg

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. While many vaccines have been deployed to date, the continual evolution of the viral receptor-binding domain (RBD) has challenged their efficacy. In particular, emerging variants B.1.1.7 (U.K.), B.1.351 (South Africa) and P.1 (Brazil) have compromised convalescent sera and immunotherapies that received emergency use authorization1–3. One potential alternative to avert viral escape is the use of camelid VHHs or nanobodies, which can recognize epitopes often inaccessible to conventional antibodies4. Here, we isolate anti-RBD nanobodies from llamas and “nanomice” we engineered to produce VHHs cloned from alpacas, dromedaries and camels. We identified two sets of highly neutralizing nanobodies. Group 1 circumvents antigenic drift by recognizing an RBD region that is highly conserved in coronaviruses but rarely targeted by human antibodies. Group 2 is almost exclusively focused to the RBD-ACE2 interface and fails to neutralize variants carrying E484K or N501Y substitutions. Notably however, group 2 nanobodies retain full neutralization activity against variants when expressed as homotrimers, rivaling the most potent antibodies produced to date against SARS-CoV-2. These findings suggest that multivalent nanobodies overcome SARS-CoV-2 mutations through two separate mechanisms: enhanced avidity for the ACE2 binding domain, and recognition of conserved epitopes largely inaccessible to human antibodies. Therefore, while new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised.

On May 19, 2021, the Delta Variant of Concern (VOC), formerly known as the Indian VOC or B 1.617.2, became the dominant strain of SARS-CoV-2 in Scotland. The Alpha VOC (formerly known as the Kent VOC, B.1.1.7, or S gene negative) had been the dominant strain previously, but it has rapidly been replaced (appendix p 1).

New outbreak in 44 kids at a middle school in Israel 🇮🇱 with #DeltaVariant, the second such outbreak at a school this week—both Delta. Several fully vaccinated adults also infected at school. 🇮🇱 also recently stop requiring #COVID19 tests upon arrival. 🧵 https://t.co/ikH54y5aSe https://t.co/KyM0JcE5SH